Gilead's Trodelvy Fails in Lung Cancer Trial, Stock Drops Over 10%

Despite the setback, Gilead plans to explore potential benefits for certain lung cancer patients and analysts highlight the company's growth potential in HIV treatments.

• Gilead Sciences' drug Trodelvy failed to significantly extend the lives of patients with advanced or metastatic non-small cell lung cancer in a late-stage trial, causing Gilead's stock to fall more than 10%.
• Despite the setback, some analysts believe the stock drop is an overreaction, highlighting Gilead's long-term growth potential in HIV treatments.
• Trodelvy, which contributed roughly a third of Gilead's $769 million in oncology sales during the third quarter, is already approved to treat some types of breast and bladder cancers.
• The disappointing results raise questions about the future of antibody drug conjugates, a class of treatments that combine an antibody with chemotherapy to specifically target and kill cancer cells.
• Gilead plans to discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug.

4 Articles

Investopedia Investor's Business Daily CNBC Stat News